Osteoclasts mediate the process of bone resorption. However These results demonstrate that GM-CSF and IL-3 can regulate the development of osteoclasts from recently replicated precursor cells in cultured fetal mouse long bones. However, the mechanisms by which CSFs influence osteoclast formation are difficult to determine from these studies because markers for the osteoclast progenitor and precursor do not exist. These data also provide evidence that the differentiation of osteoclast progenitors is regulated by different factors at different points in their ontogeny.
Introduction
Osteoclasts are multinticleated giant cells that mediate the process of bone resorption (1) (2) (3) (4) . Osteoclasts do not replicate by cell division (5) (6) (7) . Instead, they increase their size and number through the fusion and incorporation of a terminally differentiated cell, the osteoclast precursor. Osteoclast precursors are believed to originate from hematopoietic cells (8-1 1) , and their replicating parent cell has been termed the osteoclast progenitor. Little is known about the mechanisms that regulate osteoclast progenitor cell replication or differentiation.
Many analogies exist between the osteoclast precursor cell and the macrophage (12) (13) (14) , including the ability of macrophages to become multinucleated, destroy connective tissue, and release mineral from devitalized bone particles. However, recent experiments have demonstrated that macrophage giant cells do regulate the replication and differentiation of myeloid (macrophage-granulocyte) progenitor cells (18) (19) (20) are well defined and have been termed colony-stimulating factors (CSFs).' Four CSFs have been described: interleukin 3 (IL-3 or multi-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), colony-stimulating factor 1 (CSF-1, or M-CSF) and granulocyte colony-stimulating factor (G-CSF). IL-3 and GM-CSF stimulate the production of both macrophages and granulocytes, whereas CSF-I and G-CSF enhance the production ofonly macrophages or granulocytes, respectively.
To determine if factors that regulate myeloid cell production also regulate osteoclast formation, we studied the ability of two CSFs, IL-3 and GM-CSF, to alter the formation and bone-resorbing activity ofosteoclasts and the differentiation ofreplicating osteoclast progenitor cells into osteoclasts in cultured fetal mouse long bones.
Methods
Tissue culture. Radii and ulna from 18 day fetal mice were studied because they can be easily cultured in vitro and because they possess fully developed marrow cavities (21) . We used two culture protocols for our experiments.
Protocol 1 was designed to examine the direct effects of CSFs on resorption. Bones were prelabeled with "Ca (Amersham Corp., Arlington Heights, IL) by injecting 100 uCi into the mothers 24 h before sacrifice. They were dissected free of surrounding muscle and fibrous tissue and their cartilaginous ends were removed using previously described techniques (22, 23) . Bones were precultured in BGJ medium (Grand Island Biological Corp., Grand Island, NY) for 24 h immediately after dissection to remove readily exchangeable 45Ca. All media were supplemented with 5% (vol:vol) fetal bovine serum that had been heated to 570C for 3 h and treated with dextran-coated charcoal to removed endogenous stimulators of resorption (5) . After preculture bones were transferred to experimental medium for 72 h. Cultures were terminated by placing the bones in 5% TCA for 1 h. Aliquots of medium and the TCA extract of the bones were counted for "Ca by liquid scintillation. Bone resorption was measured as the percentage of total "5Ca (medium + bone) that was in the medium at the end of the experiments. Results were expressed as treated to control (T/C) ratios to allow data from multiple experiments to be compared. Protocol 2 was designed to examine the effects of pretreating the cultures with CSFs. Bones prelabeled with 45Ca were placed in medium that contained CSFs immediately after dissection and cultured for 48 h (pretreatment period). Bones were then transferred and cultured for various times (treatment period) in either control medium or medium that contained parathyroid hormone (PTH). PTH was added to the treatment medium to increase the rate that new osteoclasts formed. In these experiments resorption rates were measured only during the treatment period.
Histology. Bones not labeled with "5Ca were also cultured according to protocol 2 and examined histologically. At the conclusion of an experiment bones were fixed in 1.25% (vol:vol) glutaraldehyde in phosphate buffer and embedded in glycol-methacrylate. Three micron sections were stained with either hematoxylin-eosin or toluidine blue. Osteoclasts in midsections of the bones were identified by their proximity to bone, characteristic cytoplasm and multinucleation (1) (2) (3) (4) (5) 
Results
Using culture protocol 1, bovine PTH, a stimulator ofosteoclastic activity, increased resorption in these cultures after 72 h by about twofold (Table I ). In contrast, GM-CSF (10 to 100 U/ml) and IL-3 (300 U/ml) were either without effect or slightly inhibitory. However, both CSFs enhanced myeloid cell colony formation in semisolid agar cultures of mouse bone marrow cells (Table  II) . All experiments described in Tables I and II have been repeated at least once with identical results.
We next examined the effects ofpretreating the cultures with CSFs (protocol 2). In bones pretreated in control medium, a subsequent 48-h treatment with PTH increased both the rate of resorption and the number of osteoclasts per bone by about twofold (Table III) . PTH also tended to increase the number of nuclei per osteoclast. However, this effect was small and not always significant. Pretreatment of the cultures with CSFs did not alter 45Ca release, osteoclasts per bone section or nuclei per osteoclast in bones transferred to either control or PTH containing medium.
Pretreatment with GM-CSF had no effect on the number of osteoclasts in bones that were examined at the end of the pretreatment period (5.0±0.6 in the control, 4 .9±0.4 in the GM-CSF group). Similarly, GM-CSF pretreatment did not alter the percentage of osteoclast nuclei that were labeled in bones that had [3H]thymidine added to their pretreatment medium (t = 0 in Fig. 1 A) . However, the percentage of labeled osteoclast nuclei in either group after the pretreatment period was small (< 2%). Results are expressed in one column to save space since the SEM for both control groups was 5%.
* Significantly different from control P < 0.01, *P < 0.05.
In contrast, GM-CSF pretreatment increased both the number of myeloid cells in the marrow space of these bones and the percentage of myeloid cells that were [3H]thymidine labeled (Table IV) . A repeat of the experiments described in Tables III  and IV yielded identical results.
In bones that were pretreated in control medium that contained [3H]thymidi~ne and then transferred to medium that contained high concentrations of cold thymidine, treatment with PTH for 48 h markedly increased the percentage of labeled osteoclast nuclei compared to bones that were maintained in control medium (t = 24 and 48 in Fig. 1 A) .
There was no significant effect on the percentage of labeled osteoclast nuclei of pretreating bones with GM-CSF if bones were subsequently treated in control medium for up to 48 h or with PTH for 24 h. In contrast, in bones that were treated with PTH for 48 h, GM-CSF pretreatment decreased the percentage of labeled osteoclast nuclei by about half compared to bones pretreated in control medium (t = 48 in Fig. I A) .
The inhibitory effects that GM-CSF pretreatment had on the labeling of osteoclast nuclei in PTH treated bones in Fig. 1 A was not altered when [3H]thymidine without cold thymidine was present in both the pretreatment and treatment medium (Fig. 1 B) . Hence, this effect did not appear to result from the rapid turnover and dilution of labeled thymidine during the treatment period (when cold thymidine was in the medium).
Pretreatment ofbone with IL-3 for 48 h had effects that were similar to those of GM-CSF (Fig. 1 C) . In bones transferred to It is also possible that CSFs directed the differentiation of a common osteoclast-myeloid progenitor cell away from the osteoclast precursor cell pathway and towards that of myeloid cells. This hypothesis is supported by the ability ofGM-CSF to increase both the number of myeloid cells in these cultures and the percentage of myeloid cells that were derived from recently repli- [3H]thymidine (2 AsCi/ml, 400 nM). Treatment media contained 100
AiM cold thymidine without labeled thymidine. Our results also suggest that the processes of osteoclast formation and bone resorption are regulated at two points. CSFs appear to influence the number of osteoclast precursors that are available for incorporation into osteoclasts but have little direct effect on osteoclast formation. In contrast, PTH appears to increase the number of osteoclasts in bone by increasing the recruitment of available precursors into new osteoclasts. In addition, PTH is also capable of activating bone resorbing activity in existing osteoclasts by an indirect mechanism (29) .
